Home › Companies › Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics, Inc. (WHWK) proxy voting records
How asset managers voted at Whitehawk Therapeutics, Inc.’s shareholder meetings, one page per
proxy season, compiled from the votes funds and managers report on SEC Form N-PX and
the company’s own results on Form 8-K.
- TickerWHWK
- CUSIP issuer number00032Q
- SEC CIK1422142
Recent shareholder votes
- June 11, 2026 annual meeting (2025-2026 proxy season): 5 items in Whitehawk Therapeutics, Inc.'s official results (Form 8-K, filed June 12, 2026); lowest support 79% of votes cast (To approve, on an advisory basis, the compensation of the named…). Full results and how funds voted.
- June 11, 2025 annual meeting (2024-2025 proxy season): 5 items in Whitehawk Therapeutics, Inc.'s official results (Form 8-K, filed June 13, 2025); lowest support 79% of votes cast (Elect Director: Anupam Dalal, M.D.). Full results and how funds voted.
- February 28, 2025 special meeting (2024-2025 proxy season): 5 items in Whitehawk Therapeutics, Inc.'s official results (Form 8-K, filed March 4, 2025); lowest support 59% of votes cast (The Equity Plan Increase Proposal). Full results and how funds voted.
- June 11, 2024 annual meeting (2023-2024 proxy season): 4 items in Whitehawk Therapeutics, Inc.'s official results (Form 8-K, filed June 12, 2024); lowest support 69% of votes cast (Elect Director: Neil Desai, Ph.D.). Full results and how funds voted.
Each line is the company’s own Form 8-K tally as shown on that season’s page; support is FOR as a share of votes cast.
Proxy seasons
Earlier seasons list this company under the names
WHITEHAWK THERAPEUTICS INC.; AADI BIOSCIENCE INC., as its holders filed it.
Explore Whitehawk Therapeutics, Inc. in the interactive database
The seasons are grouped by the issuer number in the company’s CUSIP, not by
its name. Ticker as listed by the SEC on November 6, 2026.
This page is rebuilt weekly; built November 9, 2026.